NCT03951116: Study of FCN-437c in Patients With Advanced Solid Tumors

NCT03951116
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled unstable central nervous system (CNS) metatases – see trial for details
https://ClinicalTrials.gov/show/NCT03951116

Comments are closed.

Up ↑